Sema4 (NASDAQ:SMFR) Coverage Initiated at The Goldman Sachs Group

Research analysts at The Goldman Sachs Group assumed coverage on shares of Sema4 (NASDAQ:SMFRGet Rating) in a note issued to investors on Thursday, The Fly reports. The brokerage set a “buy” rating and a $3.50 price target on the stock. The Goldman Sachs Group’s price objective indicates a potential upside of 88.17% from the company’s current price.

SMFR has been the topic of several other research reports. Cowen cut their price target on Sema4 from $13.00 to $5.00 in a report on Monday, May 16th. Zacks Investment Research upgraded Sema4 from a “hold” rating to a “buy” rating and set a $2.00 target price on the stock in a research note on Wednesday, May 25th. Finally, Compass Point decreased their target price on shares of Sema4 to $5.00 and set a “na” rating for the company in a research report on Monday, May 16th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Sema4 presently has an average rating of “Buy” and an average price target of $6.08.

Shares of NASDAQ:SMFR traded up $0.01 on Thursday, reaching $1.86. 82,523 shares of the company’s stock were exchanged, compared to its average volume of 2,222,254. The business’s 50-day moving average is $2.35 and its two-hundred day moving average is $3.59. The company has a quick ratio of 3.72, a current ratio of 4.08 and a debt-to-equity ratio of 0.03. Sema4 has a fifty-two week low of $1.49 and a fifty-two week high of $15.21.

Sema4 (NASDAQ:SMFRGet Rating) last announced its quarterly earnings data on Thursday, May 12th. The company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.02. The business had revenue of $53.94 million for the quarter, compared to the consensus estimate of $48.00 million. Equities analysts anticipate that Sema4 will post -0.76 EPS for the current year.

In other news, insider Eric Schadt acquired 100,000 shares of the company’s stock in a transaction dated Friday, May 20th. The shares were bought at an average price of $1.92 per share, with a total value of $192,000.00. Following the purchase, the insider now owns 243,380 shares of the company’s stock, valued at $467,289.60. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Keith A. Meister acquired 11,437,500 shares of the business’s stock in a transaction dated Friday, April 29th. The stock was purchased at an average price of $4.00 per share, with a total value of $45,750,000.00. Following the acquisition, the director now owns 26,931,250 shares of the company’s stock, valued at $107,725,000. The disclosure for this purchase can be found here. Over the last ninety days, insiders bought 14,037,500 shares of company stock valued at $55,942,000 and sold 33,099 shares valued at $79,156.

Institutional investors and hedge funds have recently made changes to their positions in the company. Royal Bank of Canada bought a new stake in Sema4 during the third quarter worth approximately $36,000. Victory Capital Management Inc. boosted its stake in shares of Sema4 by 92.4% during the 1st quarter. Victory Capital Management Inc. now owns 21,614 shares of the company’s stock worth $46,000 after acquiring an additional 10,383 shares in the last quarter. CIBC Asset Management Inc acquired a new position in shares of Sema4 in the 4th quarter worth $56,000. Gabelli Funds LLC raised its position in shares of Sema4 by 80.0% during the first quarter. Gabelli Funds LLC now owns 22,500 shares of the company’s stock worth $69,000 after purchasing an additional 10,000 shares during the period. Finally, Mirabella Financial Services LLP purchased a new stake in shares of Sema4 during the fourth quarter valued at $74,000.

Sema4 Company Profile (Get Rating)

Sema4 Holdings Corp., doing business as Sema4, operates as a health information company that enhances diagnosis, treatment, and prevention of disease through data. The company provides Centrellis, an AI-driven health intelligence platform that delivers comprehensive insights to biopharma to accelerate the drug discovery, development, and commercialization life-cycle, as well as analytics for actionable insights, pre-clinical and clinical trial support, and advanced sequencing services.

Featured Stories

The Fly logo

Want More Great Investing Ideas?

Receive News & Ratings for Sema4 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sema4 and related companies with MarketBeat.com's FREE daily email newsletter.